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proteasome function and redox as well as metabolic home-
ostasis. These findings provide the first evidence that links 
impaired autophagy to X-ALD, which may yield a therapy 
based on autophagy activators for adrenomyeloneuropathy 
patients.
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Introduction
In addition to the ubiquitin–proteasome pathway, macro-
autophagy (autophagy, herein) is the major cellular process 
responsible for protein turnover in eukaryotic cells [30, 37, 
55]. Autophagy is initiated by a double-membrane structure 
that closes to form an autophagosome, which contains cyto-
plasmic material, including organelles, protein aggregates 
and lipids. Next, the autophagosome fuses with endosomes/
Abstract X-linked adrenoleukodystrophy (X-ALD) is 
a rare neurometabolic disease characterized by the accu-
mulation of very long chain fatty acids (VLCFAs) due to 
a loss of function of the peroxisomal transporter ABCD1. 
Here, using in vivo and in vitro models, we demonstrate 
that autophagic flux was impaired due to elevated mam-
malian target of rapamycin (mTOR) signaling, which con-
tributed to X-ALD pathogenesis. We also show that excess 
VLCFAs downregulated autophagy in human fibroblasts. 
Furthermore, mTOR inhibition by a rapamycin derivative 
(temsirolimus) restored autophagic flux and inhibited the 
axonal degenerative process as well as the associated loco-
motor impairment in the Abcd1−/Abcd2−/− mouse model. 
This process was mediated through the restoration of 
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lysosomes to form a single-membrane autolysosome that 
degrades the sequestered material [42, 53, 59, 77].
Autophagy occurs at low basal levels in almost all cells, 
but it increases rapidly and strongly under certain condi-
tions such as starvation, high energy demands [42, 53], oxi-
dative stress and protein aggregate accumulation [28, 75].
A growing body of evidence indicates that constitutive 
autophagy is indispensable for maintaining neural tissue 
homeostasis and normal function. Dysfunctional autophagy 
has been observed during neurodegeneration in both in 
vivo animal models [10, 33, 62, 86, 87, 92] and in vitro pri-
mary neuronal cultures [6, 38, 70]. Insufficient autophagy 
is characterized by the accumulation of autophagic struc-
tures and has been observed in the brains of patients with 
neurodegenerative diseases, particularly those associated 
with protein aggregates such as Alzheimer’s (AD), Parkin-
son’s and Huntington’s diseases (HD) [58].
In this study, following previous observations of poly-
ubiquitinated protein accumulation in X-linked adrenoleu-
kodystrophy models [39] (X-ALD: McKusick no. 300100), 
we investigated whether autophagy is altered in X-ALD 
and the extent to which this impairment contributes to the 
axonal degeneration pathophysiology observed in this dis-
ease. X-ALD is a severe and often lethal inherited neuro-
metabolic disorder characterized by progressive demyeli-
nation in the central nervous system, axonopathy in the 
spinal cord and adrenal insufficiency [13, 15, 57]. X-ALD 
results from a loss of function by the peroxisomal ABCD1 
fatty acid transporter, resulting in VLCFAs accumula-
tion in the target organs and plasma caused by impaired 
VLCFAs import into the peroxisome, which decreases the 
peroxisomal beta-oxidation enzyme substrate [19, 83, 85, 
88]. Three major disease variants have been described. 
One variant is a late-onset form that affects adults and is 
referred to as adrenomyeloneuropathy (AMN), which is 
characterized by peripheral neuropathy and distal axonopa-
thy in corticospinal tracts of spinal cords undergoing spas-
tic paraparesis as a major symptom without brain inflam-
matory demyelination. Two ultimately lethal forms include 
cerebral demyelination and neuroinflammation; one is an 
adult form referred to as cerebral adrenomyeloneuropa-
thy (cAMN), and the other is a childhood form referred 
to as cerebral childhood adrenoleukodystrophy (cCALD). 
All clinical phenotypes can occur within the same family; 
thus, the phenotype and genotype do not correlate [13, 15, 
57]. In recent years, we and others have shown that excess 
VLCFAs generate reactive oxygen species (ROS) and this 
together with energetic imbalances underlie disease patho-
genesis [18, 22, 63, 76]. However, the method by which 
excess VLCFAs result in adrenal and spinal cord patholo-
gies remains elusive, including whether or not they trigger 
central demyelination. Therapeutic advances include allo-
geneic bone marrow transplant [2] and gene therapy [9]; 
although, these therapies can only be applied to a subset of 
patients upon demyelination onset within a narrow window 
of opportunity. A satisfactory pharmacological treatment 
has not yet been identified [4].
Here, we used biochemical, morphological and func-
tional assays to directly analyze the autophagic system sta-
tus in X-ALD fibroblasts, patient brains and X-ALD mouse 
models (Abcd1− and Abcd1−/Abcd2−/−). We report aber-
rant mTOR signaling that causes autophagy impairment as 
a mechanistic and pivotal component of X-ALD pathogen-
esis. Based on preclinical test results from a mouse model 
using the rapamycin analog temsirolimus, we propose 
using rapamycin-related mTOR inhibitors as a potential 
therapeutic approach for X-ALD.
Materials and methods
Antibodies and reagents
The following antibodies were used for Western blots: 
γ-tubulin and DNP (2,4-dinitrophenylhydrazone) (Sigma); 
LC3 (Nanotools), phospho-p70S6 kinase (Thr389), phos-
pho-ULK1 (Ser757), p70S6 kinase and ULK1 (Cell Sign-
aling Technology); polyUbiquitin (Dako) and K48-linked 
polyUbiquitin (Cell Signaling); amyloid precursor protein 
(Boehringer); p62 and 8-oxodG (Abcam); Iba-1 (Wako); and 
GFAP, synaptophysin, goat anti-rabbit and anti-mouse IgG 
linked to horseradish peroxidase (DakoCytomation). The 
fluorogenic peptides Suc-Leu-Leu-Val-Tyr-7-amido-4-methyl-
coumarin (Suc-LLVT-AMC) and 7-amino-4-methylcoumarin 
(AMC) were obtained from Calbiochem. Hexacosanoic acid 
(C26:0) and bafilomycin A1 were purchased from Sigma.
Human brain samples
Brain tissue (frontal lobe unaffected white matter for patients 
and controls, plus affected white matter of parietal and 
occipital lobes) was obtained from patients with cerebral 
adrenoleukodystrophy (cCALD), cerebral adrenomyeloneu-
ropathy (cAMN) and healthy age-matched male control 
subjects from the Brain and Tissue Bank for Developmen-
tal Disorders at the University of Maryland, Baltimore [74] 
(Supplemental Table 1). There was no available tissue from 
pure AMN patients in this Bank, which prevented us from 
comparisons to this phenotype. Informed written consent 
was obtained from all patients or their legal representatives; 
the local ethics committee approved the studies.
Mouse colonies
The methods in this study were employed in accord-
ance with the Guide for the Care and Use of Laboratory 
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Animals published by the US National Institutes of 
Health (NIH publication No. 85-23, revised 1996) as well 
as the ethical committees of IDIBELL and the Generalitat 
de Catalunya (DAAM 3546). The generation and geno-
typing of Abcd1− (Abcd1Tm1Kds) and Abcd2−/− (Abcd2T-
m1Apuj) mice have been previously described [16, 46, 64, 
65]. The Abcd1− mice in a 129sv background were a 
kind gift of Dr Kirby Smith (KKI, Baltimore, MD) [46]. 
The Abcd1- and Abcd1−/Abcd2−/− mice were kept at 
22 °C with equal periods of darkness and light and had 
free access to water and food. All mice used for experi-
ments were on a pure C57BL/6 J background. Animals 
were killed and tissues were recovered and conserved at 
−80 °C.
Treatments and locomotor experiments
Two X-ALD mouse models were used in this study. The 
first model was Abcd1− mice that exhibit biochemical 
signs of pathology, including oxidative stress [17] and 
altered energy homeostasis [23]; however, the first clini-
cal signs of AMN (axonopathy and locomotor impairment) 
appear at 20 months [64, 65]. We characterized the bio-
chemical signs of adult AMN in these mice. The second 
model was mice with a double gene knockout of both the 
Abcd1 and Abcd2 transporters (Abcd1−/Abcd2−/−). Com-
pared with the Abcd1− mice, the Abcd1−/Abcd2−/− mice 
display enhanced VLCFAs accumulation in the spinal cord 
[64], higher levels of oxidative damage to proteins [20], 
and a more severe AMN-like pathology with an earlier 
onset at 12 months of age [16, 64, 65]; therefore, this is 
the preferred model for assaying therapeutic strategies. 
Notably, no disease-causative role for ABCD2 has been 
demonstrated; however, its absence induces a partially 
overlapping fatty acid pattern compared with the Abcd1− 
dependent biochemical phenotype [19, 43]. We assessed 
the clinical signs of AMN in these double Abcd1−/
Abcd2−/− mice. The mice used for the experiments herein 
were produced using a pure C57BL/6 J background. Gen-
eration and genotyping for Abcd1− and Abcd1−/Abcd2−/− 
mice have been previously described [46, 64]. For the 
temsirolimus treatments, the Abcd1−, Abcd1−/Abcd2−/− 
and wild-type littermate mice were separated into control 
and treated groups. Temsirolimus (LC Laboratories) was 
administered through intraperitoneal injections of 20 mg/
kg three times a week [52, 67]. We first tested different 
dosages to minimize unwanted effects. Continuous tem-
sirolimus administration over 3 months at 20 mg/kg pro-
duced substantial weight loss, between 15 and 20 % of the 
body weight (data not shown), which is consistent with 
previous observations in rodents [84]. Thus, we alternated 
3-week rest periods between each month of the 3 months 
of treatment to a total period of 4.5 months, with mice 
starting treatment at 12 months and being killed after loco-
motor tests at 17 months of age. Under these conditions, 
no significant weight loss was observed, indicating that 
the protocol with resting periods was more suitable. We 
provided the control mice with a mock injection that con-
tained buffer at the same frequency. The treadmill experi-
ment was performed exactly as previously described [44, 
56]. We measured the latency to falling off the belt (shock 
time) and number of shocks received. The bar cross exper-
iment was performed as previously described [16, 44, 56]. 
Mock- and drug-treated mice in each litter were simulta-
neously tested using the treadmill and bar cross for both 
genotype and treatment in a blind study.
Cell culture and treatment
Skin biopsies were used to prepare fibroblasts and were 
collected in accordance with the institutional guidelines 
for sampling, including informed consent from the per-
sons involved or their representatives (12/062). Fibroblasts 
were obtained from pure AMN patients and healthy age-
matched male control subjects with an age ranging from 
31 to 52 years. Primary human fibroblasts were cultured 
in DMEM (containing 10 % fetal bovine serum, 100 U/ml 
penicillin and 100 µg streptomycin) at 37 °C in humidified, 
5 % CO2/95 % air. Unless otherwise stated, the experiments 
were performed with cells at 80 % confluence. Control and 
X-ALD human fibroblasts were treated in medium con-
taining fetal bovine serum (10 %) for 24 h with ethanol as 
control or C26:0 (50 μM). For starvation conditions, after 
washing, the cells were changed from a full growth medium 
(low proteolysis medium, L) to Krebs–Henseleit medium 
(118.4 mM NaCl, 4.75 mM KCl, 1.19 mM KH2PO4, 
2.54 mM MgSO4, 2.44 mM CaCl2·2H2O, 28.6 mM 
NaHCO3, and 10 mM glucose) containing 10 mM HEPES, 
pH 7.4 (high proteolysis medium, H) and incubated for 4 h 
or less at 37 °C.
Autophagy analysis in cultured cells
For pulse-chase experiments, human control and X-ALD 
patients’ fibroblasts were incubated for 48 h in fresh full 
medium with 1 µCi/ml [3H]valine (Hartmann Analytic 
GmbH) followed by a 24 h chase in fresh full medium 
containing 10 mM l-valine to degrade short-lived proteins 
[21]. Next, all cultures were incubated for the indicated 
times in Krebs–Henseleit medium with 10 mM HEPES, 
pH 7.4, 10 mM valine and the additional components indi-
cated. Protein degradation was analyzed 1 h thereafter to 
ensure the maximum effects of the various added compo-
nents and for only 3 h to avoid possible secondary effects. 
We calculated protein degradation at two 1.5-h intervals by 
measuring the net release of trichloroacetic acid-soluble 
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radioactivity from the labeled cells into the culture medium, 
which is expressed as a percentage of the protein degraded. 
The contribution of lysosomal degradation to total protein 
degradation was calculated using 20 mM NH4Cl (Sigma-
Aldrich) and 100 µM leupeptin (Peptide Institute), as previ-
ously described [21].
Autophagic flux was assessed by measuring endogenous 
LC3-II levels relative to the γ-tubulin levels after 4 h in the 
presence of 400 nM bafilomycin A1 using specific antibod-
ies. This assay was previously established using various 
autophagy modulators [31, 69, 72]. Autophagy was also 
assessed by transfecting human fibroblasts with a pEGFP-
LC3 (a generous gift of Noboru Mizushima, Tokyo Medi-
cal and Dental University) and after 48 h, the cells were 
incubated in high proteolysis medium for 2 h and the num-
ber of fluorescent dots per transfected cells were counted 
using a fluorescence microscope as previously described 
[1]. In addition, to assess autophagosome maturation, 
human fibroblasts were also transfected for 24 h with 
mRFP-GFP-LC3 (Addgene) and incubated as above. Fluo-
rescence preparations with EGFP-LC3 and RFP-GFP-LC3 
were observed and images acquired as previously described 
[24].
Reverse transcription (RT)-PCR analysis
Total RNA was isolated from homogenized spinal cords 
using the RNeasy Mini Kit (Qiagen) in accordance with the 
manufacturer’s instructions. Next, the first-strand cDNA 
was synthesized for each RNA sample using Superscript 
II reverse transcriptase (Invitrogen) and oligo-dT. Expres-
sion levels of the candidate proteasome genes were ana-
lyzed through RT-PCR using TaqMan® Gene Expression 
Assays (Applied Biosystems). The expression levels were 
relatively quantified using the ‘Delta–Delta Ct’ (ΔΔCt) 
method with RPL0 as an endogenous control. Transcript 
quantification was performed in duplicate for each sample 
[39].
Immunohistochemistry
Spinal cords were harvested from 20-month-old wild-type, 
Abcd1−/Abcd2−/− and Abcd1−/Abcd2−/− mice treated with 
temsirolimus after perfusion using 4 % paraformalde-
hyde (PFA) as previously described [16, 44, 56, 64]. The 
spinal cords were embedded in paraffin, and serial sec-
tions (5 μm thick) were cut in a transversal or longitudinal 
(1-cm-long) plane. The number of abnormal specific pro-
files was counted every 10 sections for each stain. At least 
three sections of the spinal cord were analyzed per animal 
and per stain. The sections were stained with Sudan black 
or processed through immunohistochemistry for GFAP, 
Iba-1, APP, synaptophysin, and 8-oxodG. The number of 
abnormal specific profiles was quantified, and the results 
are expressed as the mean ± standard deviation.
Electron microscopy
L1–L2 sections of mouse spinal cords were perfused 
with 3 % glutaraldehyde/4 % PFA in phosphate buffer 
(100 mM phosphate buffer, pH 7.4) at 4 °C for 24 h. 
Vibratome Sections (50–100-μm thick) were post-fixed 
in 1 % osmium tetroxide, suspended in 2 % (w/v) aque-
ous uranyl acetate for 1 h, washed three times in dis-
tilled water, dehydrated through a graded acetone series 
at 30, 50 70, 90 and 100 % and embedded in Durcupan 
ACM (Electron Microscopy Sciences) using standard 
procedures. To select the area of interest, semi-thin sec-
tions (1.5 µm) were first obtained using a diamond knife 
and stained with 1 % toluidine blue. Ultrathin sections 
were then cut, stained with Reynold’s lead citrate and 
observed using a Philips CM-10 electron microscope at 
60 kV. Lysosomal dense bodies were identified by mor-
phological criteria previously described [32] and counts 
were performed for each genotype using more than thirty 
electron micrographs (final magnification, 7,000×) col-
lected at random from four different mice.
Electrophoresis and Western blotting
Tissues were removed from euthanized mice and flash-
frozen using liquid nitrogen. The frozen tissue and human 
fibroblasts samples were homogenized in RIPA buffer 
(150 mM NaCl, 1 % Nonidet P40, 0.5 % sodium deoxycho-
late, 0.1 % SDS, 50 mM Tris, pH 8.0) containing 0.1 mM 
leupeptin and 1 mM PMSF) using a motor-driven grinder 
(Sigma-Aldrich) and then sonicated for 2 min at 4 °C in an 
Ultrasonic processor UP50H (Hielscher-Ultrasound Tech-
nology). We used polyacrylamide (10 % acrylamide) gel 
electrophoresis for 60 min at 120 V to analyze the samples. 
The resolved proteins were transferred onto nitrocellulose 
membranes and the proteins were detected using an ECL 
Western blotting analysis system followed by exposure to 
CL-XPosure Film (Thermo Scientific). Autoradiographs 
were scanned and quantified using a GS800 Densitometer 
(Bio-Rad).
To detect protein carbonyls, the proteins were trans-
ferred to nitrocellulose membranes and derivatized with 
DNPH as previously described [68]. After derivatization, 
the membranes were blocked with 5 % free fatty acid milk 
and incubated with a monoclonal anti-DNP antibody (dilu-
tion: 1/1,000, ref D8406, Sigma-Aldrich) for 36 h at room 
temperature. Goat anti-mouse IgG linked to horseradish 
peroxidase (dilution: 1/10,000, ref 2015-08, Dako, Den-
mark) was used as a secondary antibody. The protein was 
detected as described above.
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ATP levels and chymotrypsin-like activity
ATP levels were quantified as previously described [23]. 
For proteasome activity assays, the tissue was homogenized 
in an ice-cold buffer (50 mM Tris–HCl pH 7.5, 1 mM dithi-
othreitol, 0.25 M sucrose, 5 mM MgCl2, 0.5 mM EDTA 
and 2 mM ATP) using a Teflon-on-glass homogenizer and 
centrifuged at 12,000×g for 10 min. Chymotrypsin-like 
activity was determined as described [39] using Suc-LLVY-
AMC as substrate. Equal extract levels were incubated with 
the substrate (100 µM) in 100 µl of proteasome activity 
assay buffer (0.5 mM Tris–HCl, pH 7.8, 10 mM MgCl2 and 
1 mM dithiothreitol with or without 5 mM ATP) for 30 min 
at 37 °C. The reactions were quenched by adding 0.9 ml 
of cold ethanol. The free AMC fluorescence was quantified 
using a fluorescence multi-plate FLUOstar OPTIMA FL 
reader (BMG) with excitation and emission wavelengths at 
380 and 460 nm, respectively. Lactacystin (5 µM, 2 h) was 
employed to ensure assay specificity. All reactions were 
performed in duplicate and the readings were calibrated 
using standard fluorophore solutions.
Statistical analyses
Statistical significance was assessed using Student’s t test 
when two groups were compared. In analyzing multiple 
groups, we used ANOVA and Tukey’s hsd post hoc test 
to determine the significance. The data are presented as 
the mean ± SD, and p < 0.05 was considered significant 
(*p < 0.05; **p < 0.01; ***p < 0.001).
Results
Autophagy is impaired in X-ALD patients and mouse 
models
We examined the expression patterns of two molecular 
autophagy indicators in patients who suffered from the cer-
ebral forms of X-ALD: cCALD and cAMN. First, we used 
the classical autophagosome marker LC3. During macro-
autophagy activation, the cytosolic protein LC3-I is con-
verted into LC3-II by lipidation, and it specifically associ-
ates with both sides of the limiting membranes that form 
the autophagosome. LC3-II does not bind other organelles 
and is degraded in lysosomes in an autophagy-dependent 
manner. We assessed the LC3-II levels in the unaffected 
and affected brain areas of cCALD and cAMN patients as 
well as in control samples (Fig. 1a, b) and found that they 
were consistently lower in both the patients’ unaffected and 
affected brain areas. Because LC3-II levels depend on the 
rates of both autophagosome formation and conversion into 
autolysosomes (in the absence of lysosomal inhibitors), this 
decrease indicates either impaired autophagy or increased 
autophagosome–endosome/lysosome fusion. Therefore, 
we measured the levels of the multifunctional protein p62 
(also referred to as SQSTM1), which is a protein involved 
in aggresome formation that can be degraded by autophagy 
[5]. We found that p62 levels were elevated in unaffected 
areas and, more prominently, in the affected zones of both 
cCALD and cAMN patients (Fig. 1a, b). These results 
support the notion that autophagy is impaired in X-ALD 
patients.
Next, we studied both autophagy markers in an X-ALD 
mouse model at different stages of the disease. The X-ALD 
mouse model is a classic Abcd1 gene knockout model 
(Abcd1− mice), which exhibits late-onset axonopathy in 
the spinal cord without overt inflammation or demyelina-
tion; thus, it resembles adult onset adrenomyeloneuropa-
thy in humans [65]. Abcd1− mice present overt locomo-
tor disabilities and axonopathy at 20–22 months of age; 
however, oxidative damage appears very early, at approxi-
mately 3 months of age [17]. We also observed impaired 
autophagy in 12-month-old Abcd1− mouse spinal cords, as 
evidenced by lower LC3-II levels and elevated p62 levels 
compared with wild-type mice (Fig. 1c). These differences 
were not significant in 3-month-old Abcd1− mice compared 
with wild-type mice (Fig. 1c), which indicates an accumu-
lative phenotype over time.
Most lysosomes in neurons and other cell types are of 
the dense body type. They are easily identified by con-
ventional electron microscopy and we observed fewer (by 
approximately 50 %) motor neuron lysosomes of this type 
in the Abcd1− mouse spinal cord (as shown in Fig. 2 for 
20-month-old mice). Since dense bodies in neurons mainly 
derive from the cellular autophagic activity, these results 
are consistent with a decrease in autophagy.
Autophagic flux is impaired in X-ALD patient fibroblasts
To monitor autophagy and autophagic flux in X-ALD 
fibroblasts, cells were cultured as previously described 
[21] either in a serum- and amino acid-free medium 
(Krebs–Henseleit medium) to stimulate autophagy via 
the well-described starvation response (high proteolysis, 
H) or in complete medium to assess basal autophagy (low 
proteolysis, L). The fibroblasts from X-ALD patients 
exhibited lower LC3-II levels and higher p62 levels 
compared with the controls, especially in H medium 
(Fig. 3a). Because the observed variations in LC3-II 
levels (Figs. 1, 3a) can be due to either a change in its 
synthesis or degradation, human fibroblasts were treated 
with the lysosomal inhibitor bafilomycin A1 to inhibit 
LC3-II degradation. Under these conditions, LC3-II lev-
els correlated with the number of autophagosomes in the 
cells [31]. In the presence of bafilomycin A1, X-ALD 
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patients’ fibroblasts also exhibited lower LC3-II levels 
compared with control cells in both complete (L) and 
starvation (H) media (Fig. 3b). As expected, the differ-
ences in p62 levels observed in the absence of lysosomal 
inhibitors in Fig. 3a were normalized in the presence of 
bafilomycin A1 (Fig. 3b). The decrease in autophago-
somes was further confirmed by a lower (approximately 
50 % lower compared with the controls) number of flu-
orescent puncta in X-ALD fibroblasts that transiently 
expressed EGFP-LC3 (Fig. 3c). Overall, these results 
support the notion that autophagic flux is impaired in 
X-ALD fibroblasts. To further reinforce this conclusion, 
we used an mRFP-GFP-LC3 tandem reporter that has 
been found useful to trace autophagosome maturation 
[29] because, in contrast to mRFP that is more stable, 
GFP is quenched in lysosomes due to the sensitivity of 
GFP to acid environments. Since in X-ALD fibroblasts 
yellow fluorescence could be detected, and we found a 
decrease in both yellow and red fluorescence (Fig. 3d), 
these results underscore that reduced autophagosome for-
mation and not increased maturation [54] may be respon-
sible for the autophagic defect in these cells.
VLCFAs impair autophagy in human fibroblasts
In X-ALD, VLCFAs accumulate due to impaired trans-
port and subsequent degradation in peroxisomes [19, 83, 
85, 88]. Thus, we sought to determine the putative effect 
of excess hexacosanoic acid when added to primary fibro-
blasts isolated from controls and X-ALD patients.
First, we examined whether intracellular protein degra-
dation was altered upon adding excess VLCFAs by analyz-
ing the degradation of long-lived proteins under starvation 
(high proteolysis) conditions in pulse-chase experiments. 
We estimated the total level of protein degradation and, 
separately, lysosomal protein degradation using previously 
described procedures [21]. As shown in Fig. 3e, the total 
degradation of long-lived proteins was lower (approxi-
mately 35 %) in X-ALD fibroblasts compared with control 
fibroblasts. Similarly, lysosomal degradation, which mainly 
corresponds to macroautophagy under these high proteoly-
sis conditions [21], was markedly lower (approximately 
50 %). Through alternative methods, these results confirm 
the impaired X-ALD autophagy detected above and the 
causal role of excess hexacosanoic acid. Adding excess 
Fig. 1  Autophagy is downregu-
lated in brain areas of X-ALD 
patients and in spinal cords of 
Abcd1− mice. a, b Representa-
tive immunoblots for p62 and 
LC3-II in control (CTL) and in 
non-affected (NA) and affected 
(A) white matter from cCALD 
(a) and cAMN patients (b). c 
Representative immunoblots for 
p62 and LC3-II in spinal cord 
from WT and Abcd1− mice at 
3 and 12 months (m) of age. 
Protein levels are normalized 
respect to γ-tubulin (γ-tub). The 
histograms below (a and b) and 
on the right (c) show the LC3-II 
levels and the p62 levels relative 
to CTL. Values are expressed 
as mean ± SD (n = 4 samples 
by condition in a and b; n = 6 
samples by genotype and age 
in c; *p < 0.05 and **p < 0.01, 
one-way ANOVA followed by 
Tukey’s hsd post hoc test for a 
and b, Student’s t test for c)
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C26:0 inhibited the total protein and lysosomal degradation 
levels by approximately 15 and 40 %, respectively, in con-
trol fibroblasts; however, no significant additive inhibition 
was observed in X-ALD fibroblasts (Fig. 3e).
Next, we used immunoblot analyses to determine the 
LC3-II and p62 levels in cell extracts from control and 
X-ALD fibroblasts in the presence or absence of excess 
VLCFAs. In the control fibroblasts, excess VLCFAs 
induced a marked decrease in the LC3-II levels and an 
increase in the p62 levels; however, we did not observe 
a significant difference upon adding excess VLCFAs to 
X-ALD fibroblasts with previously altered basal LC3-II 
and p62 levels (Fig. 3f). These results are consistent with 
the pulse-chase experiments and, thus, suggest a causal 
effect between the excess VLCFAs and the impaired 
autophagy in X-ALD patients.
mTOR activity is enhanced in Abcd1− mice
Next, we investigated the mechanism underlying the 
impaired autophagy during X-ALD progression. The class 
III PI3 kinase complex includes BECLIN-1 and controls 
pre-autophagosome generation. Because previous studies 
have shown that lower BECLIN-1 expression may be asso-
ciated with reduced autophagic vacuole formation [66, 91], 
we first analyzed BECLIN-1 levels in the X-ALD mouse 
Fig. 2  The number of lys-
osomes decreases in spinal 
cords of Abcd1− mice. Repre-
sentative transmission electron 
microscopic areas of the cell 
bodies of motor neurons from 
ventral horns of lumbar sections 
from spinal cords in 20-month-
old WT (a, c) and Abcd1− (b, 
d) mice fixed and stained by 
conventional procedures as 
described in “Materials and 
methods”. The areas shown in c 
and d are larger magnifications 
of the fields marked with a rec-
tangle in a and b, respectively. 
Notice in d the presence of 
lipid droplets (LD) close to lys-
osomes of the dense body type 
(DB). Bar 2 µm. e The number 
of dense bodies per µm2 motor 
neuron cell area was counted in 
more than 30 randomly selected 
areas from four different mice 
per genotype. Final counts are 
shown as mean ± SD relative 
to WT (**p < 0.01, Student’s 
t test)
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Because mTOR inhibits autophagy [71], these results 
suggest that the autophagy defect observed in X-ALD is 
mTOR dependent.
Temsirolimus promotes autophagy in Abcd1− mice
Because the mTOR inhibitor rapamycin is a well-known 
autophagy inducer, we sought to test its potential therapeutic 
effect on X-ALD pathogenesis in vivo. Since rapamycin has 
poor water solubility and stability in aqueous solutions, we 
used the rapamycin ester temsirolimus. This drug has more 
favorable pharmaceutical properties and only induces mild 
side effects in humans, and it is undergoing evaluation through 
phase II and phase III clinical trials for treating certain types 
of cancer [79, 81] (NCT01026792, NCT00827684). Thus, 
we treated 10-month-old Abcd1− mice with temsirolimus 
or a vehicle (control) administered through intraperitoneal 
injection over a 4.5-month period as described above (see the 
“Materials and methods” section) [52, 67].
Before assessing the effect of temsirolimus in X-ALD, 
we confirmed that the mTOR pathway was inhibited in the 
treated mouse spinal cords. As anticipated, mice treated 
with temsirolimus exhibited lower levels of phosphoryl-
ated p70S6 K, but the total p70S6 K immunoreactivity did 
not change (Fig. 4c). Autophagy was also assessed through 
measuring the LC3-II and p62 levels using Western blots, 
which were, respectively, up- and downregulated by tem-
sirolimus in Abcd1− mouse spinal cords (Fig. 4d, e), as 
expected from mTOR inhibition.
Temsirolimus prevents oxidized protein accumulation, 
energetic failure and proteasome malfunction in Abcd1− 
mice
Former studies from our laboratory demonstrated that oxida-
tive stress is a major contributor to X-ALD progression. The 
data showed signs of oxidative damage in spinal cords from 
the X-ALD mouse model and in fibroblasts from X-ALD 
patients with direct oxidative, glycoxidative and lipoxidative 
damage to proteins, as well as altered enzymatic antioxidant 
defenses [17]. In addition, we showed that oxidative damage 
specifically affects ATP levels, which are significantly lower in 
Abcd1− mice and X-ALD fibroblasts, implying that VLCFA-
induced oxidative stress impairs energy metabolism [23]. 
Although researchers have speculated that autophagy reacti-
vation decreases the oxidative damage propagation in neural 
tissue, most studies have analyzed whether accumulation of 
aggregation-prone proteins and cell death decrease without 
directly examining cellular redox status or oxidative damage 
[8, 52, 67]. Here, we show that temsirolimus treatment consid-
erably reduced the oxidized protein levels in Abcd1− mouse 
spinal cords (Fig. 5a) and prevented the associated bioener-
getic failure [23], which normalized ATP levels (Fig. 5d).
Fig. 3  Autophagy is downregulated in fibroblasts from X-ALD 
patients. a, b Representative immunoblots for LC3 and p62 in 
extracts from control (CTL) and patients’ (X-ALD) fibroblasts incu-
bated under high (H) and low (L) proteolysis conditions and incu-
bated without (a) or with (b) the lysosomal inhibitor bafilomycin 
A1 (see the “Materials and methods” section for details). The his-
tograms below show the LC3-II levels and the p62 levels relative to 
the CTL value under high proteolysis conditions. c Representative 
fluorescence images of control (CTL) and X-ALD patients’ (X-ALD) 
fibroblasts transfected with the EGFP-LC3 plasmid for 48 h and incu-
bated 2 h under high proteolysis conditions. Bar 20 µm. The num-
ber of fluorescent dots per transfected cell is shown on the histogram 
below (at least 50 transfected cells were counted). d Representative 
fluorescence images of fibroblasts from control (CTL) and X-ALD 
patients (X-ALD) transfected with the mRFP-GFP-LC3 plasmid for 
24 h. The cells were either non incubated (low proteolysis, 0 h) or 
incubated for 2 h in Krebs–Henseleit medium (high proteolysis, 2 h) 
as indicated (two first columns of images). Bar 20 µm. The third col-
umn corresponds to higher magnification images of the square areas 
in the images of the second column. Bar 5 µm. The number of both 
yellow, which correspond to autophagosomes, and red, which cor-
respond to autolysosomes, puncta are reduced in X-ALD, indicating 
decreased autophagic flux in these cells. The fourth column shows the 
frequency distribution of intensities in a 2D scatter plot derived from 
the transfected cells, confirming this conclusion. e Control (CTL) and 
X-ALD fibroblasts (X-ALD) were treated with 50 μM of C26:0 for 
24 h. The cells were then labeled with [3H]valine in low proteolysis 
medium and total and lysosomal degradation of long-lived proteins 
were quantified in high proteolysis medium as described in “Mate-
rials and methods”. Results are presented as the percentage of the 
labeled protein degraded in 1.5 h. f Representative immunoblots for 
p62 and LC3-II in control (CTL) and X-ALD fibroblasts (X-ALD) 
treated with C26:0 as in e. The histograms below show the LC3-II 
levels and the p62 levels relative to untreated control fibroblasts. Pro-
tein levels in a, b and f were always normalized respect to γ-tub. All 
values are expressed as mean ± SD (n = 4 by genotype and condition 
in a, b, e and f; n = 3 by genotype in c; **p < 0.01 and ***p < 0.001, 
one-way ANOVA followed by Tukey’s hsd post hoc test for a, b, e 
and f, and Student’s t test for c)
◂
model. We did not observe significant differences at 3 or 
12 months in Abcd1− mouse spinal cords compared with 
wild-type mice (Fig. 4a). We also determined the activa-
tion state of mTOR, which is a major negative regulator of 
macroautophagy. This kinase inhibits autophagy under the 
nutrient-rich conditions of a high-fat diet [61, 71]. We ana-
lyzed p70S6 K, a well-known mTOR substrate, and showed 
increased p70S6 K phosphorylation in the spinal cords of 
12-month-old but not of 3-month-old Abcd1− mice com-
pared with control mice (Fig. 4a), which is consistent with 
the results in Fig. 1c. Similarly, we analyzed p70S6 K and 
the phosphorylation status of ULK1 at Ser 757 (another 
downstream target of mTOR) in X-ALD fibroblasts, which 
showed a significant increase under basal conditions (L 
medium) compared with control fibroblasts (Fig. 4b). As 
expected, we did not detect p70S6 K phosphorylation in 
the fibroblasts under starvation conditions (H medium), but 
the increase in ULK1 phosphorylation (at Ser 757) detected 
under basal conditions could be also observed, albeit to a 
lower extent, under starvation.
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Finally, our previous studies showed that the ubiquitin–
proteasome system (UPS) and immunoproteasome induc-
tion malfunctioned as a consequence of and as an adaptive 
response to oxidative stress during X-ALD pathogenesis 
[39]. Indeed, the UPS is pivotal in the rapid clearance of 
damaged, misfolded or aggregated proteins in both healthy 
and diseased states, and has been shown to play a role in 
the degradation of oxidized proteins as well [12, 26, 57]. 
Fig. 4  Temsirolimus inhibits mTOR and restores autophagy in spinal 
cord from Abcd1− mice. a Representative immunoblots for Beclin-1 
and total p70S6 K and its phosphorylated form (P-p70S6 K) in spi-
nal cords from 3- and 12-month-old WT and Abcd1− mice. The his-
tograms on the right show the Beclin-1 levels normalized respect to 
γ-tub and the P-p70S6 K/p70S6 K ratios relative to their respective 
WT values. b Representative immunoblots for p70S6 K and ULK1 
and their phosphorylated forms (P-p70S6 K and P-ULK1) in extracts 
from control (CTL) and patients´ (X-ALD) fibroblasts incubated 
under high (H) and low (L) proteolysis conditions. The histograms on 
the right show P-p70s6 K/p70S6 K and P-ULK1/ULK1 ratios rela-
tive to CTL fibroblasts under low proteolysis conditions. Representa-
tive immunoblots for p70S6 K and P-p70S6 K (c), LC3-II (d) and 
p62 (e) in spinal cords of 14-month-old WT mice untreated (WT) or 
treated with temsirolimus (WT + Tems) and Abcd1− mice untreated 
(Abcd1−) or treated with temsirolimus (Abcd1− + Tems). In c and d, 
the histograms on the right show, respectively, P-p70S6 K/p70S6 K 
ratios relative to WT values and the LC3-II levels normalized respect 
to γ-tub. In e, the histogram on the right shows the levels of p62 nor-
malized respect to γ-tub and relative to untreated WT mice. All val-
ues are expressed as mean ± SD (n = 4 samples per genotype and 
condition in b; n = 6 samples per genotype and condition in a and 
c–e; *p < 0.05, **p < 0.01 and ***p < 0.001, one-way ANOVA fol-
lowed by Tukey’s hsd post hoc test)
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Along with proteasomal degradation, autophagy constitutes 
the major route for degradation of misfolded or modified 
intracellular proteins [48]. We therefore hypothesized that 
induction of autophagy could compensate for both the pro-
teasome and immunoproteasome malfunction by increasing 
the clearance of oxidized proteins. Thereby, we examined 
the temsirolimus-mediated effects from these alterations, 
which showed that the treatment normalized the accumula-
tion of total poly-ubiquitinated proteins (Fig. 5b), and K-48 
linked poly-ubiquitinated proteins, which are known to 
be more specifically targeted for proteasomal degradation 
(Fig. 5c). The results are, in accordance with the decrease 
of oxidized proteins (Fig. 5a). Moreover, the treatment also 
normalized chymotrypsin-like proteasome activity (Fig. 5e) 
and prevented induction of the immunoproteasome subu-
nits β1i/LMP2 and β5i/LMP7 (Fig. 5f).
Temsirolimus prevents axonal degeneration in Abcd1−/
Abcd2−/− mice
Abcd1−/Abcd2−/− mice exhibit earlier, more severe 
axonopathy compared with Abcd1− mice, beginning at 
12 months of age; therefore, Abcd1−/Abcd2−/− mice are 
the preferred model for examining the clinical benefits 
of a given therapy [44, 50, 56] (see the “Materials and 
methods” section for details). The double mutants exhibit 
a neuropathological phenotype characterized by the fol-
lowing: (1) increased labeling with 8-oxo-7,8-dihydro-2′-
deoxyguanosine (8-oxodG), which is a marker of oxidative 
DNA damage, in spinal motor neurons; (2) microglio-
sis and astrocytosis, as demonstrated by Iba-1 and glial 
fibrillary acidic protein (GFAP) staining, respectively; (3) 
axonal damage, as demonstrated by amyloid precursor 
protein (APP) and synaptophysin accumulation in axonal 
swellings; and (4) scattered myelin debris, as demonstrated 
by Sudan black staining [44, 56, 64].
Thus, we treated Abcd1−/Abcd2−/− mice begin-
ning at disease onset, 12 months of age, for 4.5 months 
as described (see the “Materials and methods” section). 
As shown in Fig. 6a–s, treating Abcd1−/Abcd2−/− mice 
decreased the accumulation of axonal damage markers 
as well as the number of reactive astrocytes and reactive 
microglia to control levels. This treatment also restored the 
levels of DNA oxidation in spinal motor neurons, which 
Fig. 5  Temsirolimus reduces the accumulation of oxidized pro-
teins, normalizes energetic failure and restores proteasome altera-
tions in spinal cord from Abcd1− mice. Representative immunoblots 
for oxidized proteins (carbonylated proteins) (a), for total (b) and 
for K-48 linked (c), poly-ubiquitinated proteins in spinal cords of 
14-month-old WT mice untreated (WT) or treated with temsirolimus 
(WT + Tems) and Abcd1− mice untreated (Abcd1−) or treated with 
temsirolimus (Abcd1− + Tems). In a–c the histograms on the right, 
show, respectively, the levels of oxidized proteins (a), total poly-ubiq-
uitinated (Poly-ub) proteins (b) and K-48 linked poly-ubiquitinated 
proteins (K48-ub) (c) relative to untreated WT mice and always nor-
malized respect to the γ-tub. ATP levels (d), chymotrypsin-like (CTL) 
proteasome activities in the presence or not of ATP (e) and relative 
gene expression of 20S (β2, β1) and i-20S (β5i, β1i) proteasome 
subunits analyzed by quantitative RT-PCR (f) expressed relative to 
untreated WT mice. All values are as mean ± SD (n = 4 samples per 
genotype and condition in (e); n = 6 samples per genotype and condi-
tion in a–c and f; n = 8 per genotype and condition in d. *p < 0.05, 
**p < 0.01 and ***p < 0.001, one-way ANOVA followed by Tukey’s 
hsd post hoc test)
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Fig. 6  Temsirolimus prevents 
oxidative stress and myelin and 
axonal pathologies in spinal 
cords of 17-month-old Abcd1−/
Abcd2−/− mice. Temsirolimus 
rescues locomotor deficits in 
Abcd1−/Abcd2−/− mice. a–s 
Immunohistological analysis of 
axonal pathologies performed 
in 17-month-old WT, Abcd1−/
Abcd2−/− and Abcd1−/Abcd2−/− 
mice treated with temsirolimus 
(Abcd1−/Abcd2−/− + Tems). 
Spinal cord immunohistological 
sections were processed for a–c 
8-oxodG, d–f Iba-1, g–i GFAP, 
j–l synaptophysin, m–o APP 
and p–r Sudan black. Repre-
sentative images a, d, g, j, m 
and p for WT, b, e, h, k, n, and 
q for Abcd1−/Abcd2−/−, and 
c, f, i, l, o and r for Abcd1−/
Abcd2−/− + Tems mice are 
shown. Bars 25 µm. Small star 
indicates the motor neurons 
in a, b and c. s Quantification 
of synaptophysin and APP 
accumulation in spinal cord 
immunohistological sections 
of WT, Abcd1−/Abcd2−/− and 
Abcd1−/Abcd2−/− + Tems 
mice. t Treadmill test and u bar 
cross test have been carried out 
in 17-month-old WT Abcd1−/
Abcd2−/− and Abcd1−/Abcd2−/− 
mice treated with temsirolimus 
(Abcd1−/Abcd2−/− + Tems). 
t The latency to falling off the 
belt (time of shocks) and the 
number of shocks received 
were computed after 5 min. u 
The time spent to cross the bar 
and the numbers of slips were 
quantified. Values are expressed 
as mean ± SD (n = 5 per condi-
tion in a–s; n = 12 in t and 
u; *p < 0.05, **p < 0.01 and 
***p < 0.001, one-way ANOVA 
followed by Tukey’s hsd post 
hoc test)
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demonstrated cellular specificity for the antioxidant effects 
found for the whole spinal cords extracts in Fig. 5a.
Temsirolimus inhibits locomotor deficit progression 
in Abcd1−/Abcd2−/− mice
Locomotor deficits in Abcd1−/Abcd2−/− mice were evalu-
ated using treadmill and bar cross experiments after tem-
sirolimus treatment. In the treadmill experiment, the dou-
ble-knockout mice exhibited longer shock times and more 
shocks compared with wild-type mice, which indicate loco-
motor disability. Interestingly, temsirolimus treatment nor-
malized these parameters.
In the bar cross experiments, double-knockout mutants 
often failed to maintain their balance and displayed a 
greater tendency to slip off the bar as well as longer laten-
cies for reaching the platform at the opposite end of the 
bar [16, 44, 56]. The number of slips and time necessary 
to cross the bar were normalized following temsirolimus 
treatment (Fig. 6t, u). Overall, these data indicate that tem-
sirolimus treatment arrests disease progression in Abcd1−/
Abcd2−/− mice.
Discussion
Autophagy dysfunction has been directly associated with a 
growing number of neurodegenerative disorders [1, 48, 58, 
89]. Importantly, in previous studies, rapamycin treatment 
decreased plaques and tangles as well as ameliorated cog-
nitive defects in an AD mouse model, prevented dopamin-
ergic neurodegeneration in parkinsonian mice and reduced 
the levels of mutant ataxin-3 or mutant huntingtin as well as 
ameliorated their toxicity in vivo, which confirms previous 
evidence showing that autophagy induction is beneficial in 
models of neurodegeneration associated with protein aggre-
gates [11, 47, 52, 67, 71]. Here, we support the notion that 
impaired autophagy plays a pivotal role in pathogenesis of 
a neurodegenerative disease unrelated to protein aggregates, 
X-ALD. In cCALD and cAMN patients, Abcd1− mice and 
human X-ALD fibroblasts, we show less autophagosome 
formation as assessed by LC3-II blotting in the presence and 
absence of a lysosomal inhibitor and other well-established 
procedures. These experiments could not be performed in 
human pure AMN samples, due to sample unavailability, 
although most of the experiments have been carried out in 
the mouse model for AMN, and the fibroblasts were from 
AMN patients. Thus, we believe the encountered defects 
are common to all X-ALD phenotypes, in a similar man-
ner as the accumulation of VLCFA or the oxidative damage 
is. This decrease of autophagosome formation was associ-
ated with an increase in the endogenous autophagy sub-
strate p62 and is likely related to poly-ubiquitinated protein 
accumulation, which has previously been demonstrated [39]. 
Impaired autophagy in X-ALD may be due to greater activ-
ity by the autophagy negative regulator mTOR. Consistent 
with these data, we demonstrated that treating the mouse 
model with temsirolimus, a rapamycin analog that inhib-
its mTOR, induced autophagy, which enhanced autophagy 
substrate clearance. In addition, temsirolimus restored pro-
teasome activity, prevented immunoproteasome induction, 
and, more importantly, inhibited axonopathy progression 
as well as clinical manifestations. This activity was medi-
ated by normalized signs of oxidative damage and oxida-
tive lesions in protein and DNA as well as the associated 
energetic homeostasis. Figure 7 summarizes these effects, 
which indicates that normalizing autophagic function is key 
for disease progression and, thus, highlights autophagy as a 
prime therapeutic target. The characteristics seen with the 
autophagy failure during pathogenesis of X-ALD have both 
similarities and differences when compared with those found 
in certain forms of lysosomal storage diseases and other neu-
rodegenerative diseases such as AD and HD. In these cases, 
autophagic flux was impaired, the number of autophagic 
vacuoles increased and autophagic substrates accumulated in 
the affected tissues [49, 89]. However, in Duchenne’s mus-
cular dystrophy, impaired autophagolysosome formation has 
been observed and is characterized by increased p62 as well 
as decreased LC3-II and mTOR activation, as we observed 
in X-ALD. This effect is due to chronic oxidative stress pro-
duced by NADPH oxidase in mdx mice [60].
VLCFAs accumulate in X-ALD, and most cells respond 
to a moderate lipid influx by increasing macroautophagic 
flow [78]. Similarly, Baarine et al. [3] showed in 2012 that 
acute VLCFAs exposure could induce autophagy activation, 
lysosomal membrane destabilization and lysosomal localiza-
tion changes in wild-type 158 N murine oligodendrocytes. 
Moreover, upregulated autophagy in response to an acute 
increase in free saturated fatty acids (e.g., palmitate) was 
demonstrated in pancreatic beta cell lines (INS-1), neuro-
blastoma (SK-N-SH), myoblasts (C2C12), and hepatocytes 
(HepG2) [36]. Furthermore, acute oleic, but not palmitic 
acid, exposure induces autophagy in HepG2 cells through a 
mechanism that depends on oxidative stress [51]; however, 
another group demonstrated that acute exposure to pal-
mitic, but not oleic acid, increases autophagy independent of 
mTOR in mouse embryonic fibroblasts [80]. Together, these 
data suggest that free fatty acids regulate autophagy in spe-
cific cell types and under particular conditions (acute expo-
sure to free fatty acids). In this study, we provide the first 
evidence that autophagy is impaired by VLCFAs in control 
fibroblasts under basal conditions. We did not observe signif-
icant changes in X-ALD fibroblasts, which may be explained 
by the strong inhibition of autophagy already present, most 
likely due to the increased basal levels of VLCFAs in these 
cells that may mitigate any exacerbated or adaptive response. 
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Koga et al. [34] observed a reduction in autophagy after 
acute exposure to a high lipid concentration, or a particular 
type of lipid or after chronic lipid stimulation (high-fat diet). 
Mechanism-based studies implicate an inhibitory effect by 
free fatty acids on autophagy in cells or animals exposed to 
either high concentrations of free fatty acids (palmitate and 
oleate) or a prolonged high-fat diet. These observations indi-
cate that there is a primary defect in the fusion of autophago-
somes and lysosomes, which is secondary to changes in the 
lipid composition of those vesicles [34]. These observations 
are particularly relevant for X-ALD because VLCFAs accu-
mulation has been shown to destabilize and increase the 
viscosity in model membranes [27]. We recently proposed 
that excess VLCFAs, either as free fatty acids or part of a 
lipid complex, interfere with mitochondria membranes and 
produce ROS through the mitochondrial oxidative phospho-
rylation system (OXPHOS) [18, 45]. Thus, we posit a simi-
lar mechanism by which excess VLCFAs affect lysosomal 
membranes and inhibit autophagic flux.
Our results highlight autophagy as an efficient, alterna-
tive antioxidant defense mechanism that removes oxidized 
products, not free radicals, as suggested [25]. In addition, 
a recent study showed that rapamycin directly controls 
mitochondrial function through promoting aerobic glyco-
lysis over mitochondrial respiration, which reduces oxygen 
consumption and generates fewer ROS [41]. Furthermore, 
previous data showed that TOR1 gene deletion extends the 
chronological life span in Saccharomyces cerevisiae by 
increasing mitochondrial respiration via enhanced trans-
lation of the mtDNA-encoded oxidative phosphorylation 
complex subunits [7]. Simultaneous restoration of ener-
getic and redox homeostasis through enhanced autophagy 
induced by temsirolimus is most likely a key factor in 
arresting disease progression.
Accumulating evidence shows that autophagy stimula-
tion and ROS accumulation are linked to multiple patho-
logical processes, including cancer, neurodegenerative 
diseases, type-II diabetes, immune diseases and aging [14, 
40]. It is tempting to speculate that the impaired autophagy 
observed in X-ALD may exacerbate oxidative stress and 
mitochondrial damage, playing a pivotal role in disease 
progression. Autophagy inhibition produces neurodegen-
eration in vivo through ubiquitinated protein accumula-
tion, increased ROS and dysfunctional mitochondria [35, 
Fig. 7  Model illustrating the 
role of autophagy in the eti-
opathogenesis of axonal degen-
eration in X-adrenoleukodystro-
phy. In X-ALD, VLCFA excess 
induces production of ROS 
and accumulation of oxidized 
proteins and damaged orga-
nelles in spinal cord. VLCFA 
also produce impairment of 
autophagic flux by inhibition 
of autophagosome formation. 
All these alterations (red lines) 
and others result in axonal 
degeneration. The mTOR 
inhibitor temsirolimus (green 
lines) restores autophagic flux, 
prevents oxidized proteins 
accumulation and bioenergetic 
failure, leading to protection 
against axonal degeneration and 
associated locomotor disability 
in the Abcd1−/Abcd2−/− mouse 
model
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48, 90]. In turn, low mitochondrial ROS levels, which are 
produced during starvation for example, are necessary for 
regulating (through posttranslational oxidative modifica-
tion) Atg4 activity when autophagy activation is part of a 
survival pathway [73]. These observations are supported 
by results from wild-type mice subjected to starvation 
combined with the antioxidant NAC, in which autophagy 
induction was inhibited, further demonstrating crosstalk 
between these pathways [82].
Our successful experiments using the rapamycin analog 
temsirolimus in the Abcd1− and the Abcd1−/Abcd2−/− 
mouse model suggest that the therapeutic potential of 
autophagy induction merits serious consideration. Mice 
treated with temsirolimus exhibited reduced oxidative 
damage and improved energetic homeostasis, protea-
some activity, neuropathology and scores from two clini-
cal experiments that demonstrate axonopathy. Our results 
demonstrate a neuroprotective role by temsirolimus in 
vivo, which suggests a mechanism that attenuates oxida-
tive stress levels. Taken together, our findings strongly sug-
gest that temsirolimus treatment is an attractive therapeutic 
option for X-adrenomyeloneuropathy patients.
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